South Korea · Delayed Price · Currency is KRW D&D Pharmatech Statistics
Total Valuation
D&D Pharmatech has a market cap or net worth of KRW 2.04 trillion. The enterprise value is 2.01 trillion.
| Market Cap | 2.04T |
| Enterprise Value | 2.01T |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
D&D Pharmatech has 45.84 million shares outstanding. The number of shares has increased by 2.89% in one year.
| Current Share Class | 45.84M |
| Shares Outstanding | 45.84M |
| Shares Change (YoY) | +2.89% |
| Shares Change (QoQ) | +3.43% |
| Owned by Insiders (%) | 20.85% |
| Owned by Institutions (%) | 18.76% |
| Float | 34.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 743.29 |
| PB Ratio | 15.25 |
| P/TBV Ratio | 19.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.21, with a Debt / Equity ratio of 0.86.
| Current Ratio | 27.21 |
| Quick Ratio | 23.40 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.62 |
| Interest Coverage | -12.15 |
Financial Efficiency
Return on equity (ROE) is -20.48% and return on invested capital (ROIC) is -49.41%.
| Return on Equity (ROE) | -20.48% |
| Return on Assets (ROA) | -11.25% |
| Return on Invested Capital (ROIC) | -49.41% |
| Return on Capital Employed (ROCE) | -12.02% |
| Weighted Average Cost of Capital (WACC) | 12.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -939.73M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.20% in the last 52 weeks. The beta is 1.63, so D&D Pharmatech's price volatility has been higher than the market average.
| Beta (5Y) | 1.63 |
| 52-Week Price Change | +3.20% |
| 50-Day Moving Average | 55,631.00 |
| 200-Day Moving Average | 77,487.25 |
| Relative Strength Index (RSI) | 29.49 |
| Average Volume (20 Days) | 516,457 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, D&D Pharmatech had revenue of KRW 2.75 billion and -21.60 billion in losses. Loss per share was -824.34.
| Revenue | 2.75B |
| Gross Profit | 2.73B |
| Operating Income | -37.62B |
| Pretax Income | -22.69B |
| Net Income | -21.60B |
| EBITDA | -31.96B |
| EBIT | -37.62B |
| Loss Per Share | -824.34 |
Balance Sheet
The company has 152.26 billion in cash and 115.09 billion in debt, with a net cash position of 37.16 billion or 810.77 per share.
| Cash & Cash Equivalents | 152.26B |
| Total Debt | 115.09B |
| Net Cash | 37.16B |
| Net Cash Per Share | 810.77 |
| Equity (Book Value) | 134.09B |
| Book Value Per Share | 2,939.26 |
| Working Capital | 178.36B |
Cash Flow
In the last 12 months, operating cash flow was -24.89 billion and capital expenditures -41.30 million, giving a free cash flow of -24.94 billion.
| Operating Cash Flow | -24.89B |
| Capital Expenditures | -41.30M |
| Depreciation & Amortization | 5.66B |
| Net Borrowing | 224.54B |
| Free Cash Flow | -24.94B |
| FCF Per Share | -544.00 |
Margins
| Gross Margin | 99.17% |
| Operating Margin | -1,367.89% |
| Pretax Margin | -825.01% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
D&D Pharmatech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.89% |
| Shareholder Yield | -2.89% |
| Earnings Yield | -1.06% |
| FCF Yield | -1.22% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 13, 2025. It was a forward split with a ratio of 4.
| Last Split Date | Nov 13, 2025 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
D&D Pharmatech has an Altman Z-Score of 8.5 and a Piotroski F-Score of 1.
| Altman Z-Score | 8.5 |
| Piotroski F-Score | 1 |